Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Development and validation of the Heidelberg Neurological Triage System (HEINTS).

Oßwald HM, Harenberg L, Jaschonek H, Mundiyanapurath S, Purrucker JC, Rauch G, Ringleb PA, Nagel S.

J Neurol. 2019 Nov;266(11):2685-2698. doi: 10.1007/s00415-019-09472-0. Epub 2019 Jul 18.

PMID:
31321517
2.

Modular, stereocontrolled Cβ-H/Cα-C activation of alkyl carboxylic acids.

Shang M, Feu KS, Vantourout JC, Barton LM, Osswald HL, Kato N, Gagaring K, McNamara CW, Chen G, Hu L, Ni S, Fernández-Canelas P, Chen M, Merchant RR, Qin T, Schreiber SL, Melillo B, Yu JQ, Baran PS.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8721-8727. doi: 10.1073/pnas.1903048116. Epub 2019 Apr 17.

3.

Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.

Ghosh AK, Jadhav RD, Simpson H, Kovela S, Osswald H, Agniswamy J, Wang YF, Hattori SI, Weber IT, Mitsuya H.

Eur J Med Chem. 2018 Dec 5;160:171-182. doi: 10.1016/j.ejmech.2018.09.046. Epub 2018 Sep 18.

4.

[Self-assessment of treatment urgency on presentation to a neurological emergency department : Results of a patient survey].

Harenberg L, Oßwald HM, Jaschonek H, Nagel S.

Nervenarzt. 2019 Feb;90(2):175-182. doi: 10.1007/s00115-018-0623-0. German.

PMID:
30276430
5.

Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.

Ghosh AK, R Nyalapatla P, Kovela S, Rao KV, Brindisi M, Osswald HL, Amano M, Aoki M, Agniswamy J, Wang YF, Weber IT, Mitsuya H.

J Med Chem. 2018 May 24;61(10):4561-4577. doi: 10.1021/acs.jmedchem.8b00298. Epub 2018 May 15.

6.

Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.

Ghosh AK, Rao KV, Nyalapatla PR, Kovela S, Brindisi M, Osswald HL, Sekhara Reddy B, Agniswamy J, Wang YF, Aoki M, Hattori SI, Weber IT, Mitsuya H.

ChemMedChem. 2018 Apr 23;13(8):803-815. doi: 10.1002/cmdc.201700824. Epub 2018 Mar 15.

7.

A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.

Aoki M, Hayashi H, Rao KV, Das D, Higashi-Kuwata N, Bulut H, Aoki-Ogata H, Takamatsu Y, Yedidi RS, Davis DA, Hattori SI, Nishida N, Hasegawa K, Takamune N, Nyalapatla PR, Osswald HL, Jono H, Saito H, Yarchoan R, Misumi S, Ghosh AK, Mitsuya H.

Elife. 2017 Oct 17;6. pii: e28020. doi: 10.7554/eLife.28020.

8.

Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E, McNamee EN, Clambey E, Moldovan R, Reyes G, Klawitter J, Ambler K, Magee K, Christians U, Brodsky KS, Ravid K, Choi DS, Wen J, Lukashev D, Blackburn MR, Osswald H, Coe IR, Nürnberg B, Haase VH, Xia Y, Sitkovsky M, Eltzschig HK.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI94890. Epub 2017 Jun 1. No abstract available.

9.

Simultaneous Online Monitoring of Multiple Reactions Using a Miniature Mass Spectrometer.

Pulliam CJ, Bain RM, Osswald HL, Snyder DT, Fedick PW, Ayrton ST, Flick TG, Cooks RG.

Anal Chem. 2017 Jul 5;89(13):6969-6975. doi: 10.1021/acs.analchem.7b00119. Epub 2017 Jun 15.

PMID:
28520396
10.

Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.

Ghosh AK, Rao KV, Nyalapatla PR, Osswald HL, Martyr CD, Aoki M, Hayashi H, Agniswamy J, Wang YF, Bulut H, Das D, Weber IT, Mitsuya H.

J Med Chem. 2017 May 25;60(10):4267-4278. doi: 10.1021/acs.jmedchem.7b00172. Epub 2017 Apr 18.

11.

Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.

Ghosh AK, Osswald HL, Glauninger K, Agniswamy J, Wang YF, Hayashi H, Aoki M, Weber IT, Mitsuya H.

J Med Chem. 2016 Jul 28;59(14):6826-37. doi: 10.1021/acs.jmedchem.6b00639. Epub 2016 Jul 7.

12.

Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Ghosh AK, Osswald HL, Prato G.

J Med Chem. 2016 Jun 9;59(11):5172-208. doi: 10.1021/acs.jmedchem.5b01697. Epub 2016 Jan 22. Review.

13.

Design and performance of an ultra-flexible two-photon microscope for in vivo research.

Mayrhofer JM, Haiss F, Haenni D, Weber S, Zuend M, Barrett MJ, Ferrari KD, Maechler P, Saab AS, Stobart JL, Wyss MT, Johannssen H, Osswald H, Palmer LM, Revol V, Schuh CD, Urban C, Hall A, Larkum ME, Rutz-Innerhofer E, Zeilhofer HU, Ziegler U, Weber B.

Biomed Opt Express. 2015 Oct 2;6(11):4228-37. doi: 10.1364/BOE.6.004228. eCollection 2015 Nov 1.

14.

X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design.

St John SE, Therkelsen MD, Nyalapatla PR, Osswald HL, Ghosh AK, Mesecar AD.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5072-7. doi: 10.1016/j.bmcl.2015.10.023. Epub 2015 Oct 13.

15.

Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.

Ghosh AK, Martyr CD, Osswald HL, Sheri VR, Kassekert LA, Chen S, Agniswamy J, Wang YF, Hayashi H, Aoki M, Weber IT, Mitsuya H.

J Med Chem. 2015 Sep 10;58(17):6994-7006. doi: 10.1021/acs.jmedchem.5b00900. Epub 2015 Aug 25.

16.
17.

Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.

Ghosh AK, Yu X, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

J Med Chem. 2015 Jul 9;58(13):5334-43. doi: 10.1021/acs.jmedchem.5b00676. Epub 2015 Jun 24.

18.

Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.

Tomar S, Johnston ML, St John SE, Osswald HL, Nyalapatla PR, Paul LN, Ghosh AK, Denison MR, Mesecar AD.

J Biol Chem. 2015 Aug 7;290(32):19403-22. doi: 10.1074/jbc.M115.651463. Epub 2015 Jun 8.

19.

Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.

Deng X, StJohn SE, Osswald HL, O'Brien A, Banach BS, Sleeman K, Ghosh AK, Mesecar AD, Baker SC.

J Virol. 2014 Oct;88(20):11886-98. doi: 10.1128/JVI.01528-14. Epub 2014 Aug 6.

20.

Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.

Ghosh AK, Schiltz GE, Rusere LN, Osswald HL, Walters DE, Amano M, Mitsuya H.

Org Biomol Chem. 2014 Sep 21;12(35):6842-54. doi: 10.1039/c4ob00738g.

21.

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.

Ghosh AK, Osswald HL.

Chem Soc Rev. 2014 Oct 7;43(19):6765-813. doi: 10.1039/c3cs60460h. Review.

22.

A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant.

Agnihothram S, Yount BL Jr, Donaldson EF, Huynh J, Menachery VD, Gralinski LE, Graham RL, Becker MM, Tomar S, Scobey TD, Osswald HL, Whitmore A, Gopal R, Ghosh AK, Mesecar A, Zambon M, Heise M, Denison MR, Baric RS.

mBio. 2014 Mar 25;5(2):e00047-14. doi: 10.1128/mBio.00047-14.

23.

Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

J Med Chem. 2013 Sep 12;56(17):6792-802. doi: 10.1021/jm400768f. Epub 2013 Aug 15.

24.

Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E, McNamee EN, Clambey E, Moldovan R, Reyes G, Klawitter J, Ambler K, Magee K, Christians U, Brodsky KS, Ravid K, Choi DS, Wen J, Lukashev D, Blackburn MR, Osswald H, Coe IR, Nürnberg B, Haase VH, Xia Y, Sitkovsky M, Eltzschig HK.

J Clin Invest. 2012 Feb;122(2):693-710. doi: 10.1172/JCI60214. Epub 2012 Jan 24. Retraction in: J Clin Invest. 2017 Jun 1;127(6):2438.

25.

Remote conditioning in clinical practice: a type of distant healing?

Osswald H, Moerike K.

Cardiology. 2011;119(4):214-6. doi: 10.1159/000333013. Epub 2011 Oct 6. No abstract available.

PMID:
21985801
26.

Methylxanthines and the kidney.

Osswald H, Schnermann J.

Handb Exp Pharmacol. 2011;(200):391-412. doi: 10.1007/978-3-642-13443-2_15. Review.

27.

Hyperhomocysteinemia is associated with decreased erythropoietin expression in rats.

Grenz A, Hermes M, Hammel P, Roll JB, Osswald H, Kloor D.

Cell Physiol Biochem. 2010;26(3):449-56. doi: 10.1159/000320568. Epub 2010 Aug 24.

28.

In vivo stimulation of AMP-activated protein kinase enhanced tubuloglomerular feedback but reduced tubular sodium transport during high dietary NaCl intake.

Huang DY, Gao H, Boini KM, Osswald H, Nürnberg B, Lang F.

Pflugers Arch. 2010 Jun;460(1):187-96. doi: 10.1007/s00424-010-0803-7. Epub 2010 Mar 27.

PMID:
20349193
29.

Adenosine receptors and the kidney.

Vallon V, Osswald H.

Handb Exp Pharmacol. 2009;(193):443-70. doi: 10.1007/978-3-540-89615-9_15. Review.

30.

Determinants for the cAMP-binding site at the S-adenosylhomocysteine-hydrolase.

Kloor D, Hermes M, Kirschler J, Müller M, Hagen N, Kalbacher H, Stevanovic S, Osswald H.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Sep;380(3):215-22. doi: 10.1007/s00210-009-0432-x. Epub 2009 Jun 23.

PMID:
19547959
31.

17beta-Estradiol modulates apoptosis in pancreatic beta-cells by specific involvement of the sulfonylurea receptor (SUR) isoform SUR1.

Ackermann S, Hiller S, Osswald H, Lösle M, Grenz A, Hambrock A.

J Biol Chem. 2009 Feb 20;284(8):4905-13. doi: 10.1074/jbc.M807638200. Epub 2008 Dec 18.

32.

S-Adenosylhomocysteine hydrolase overexpression in HEK-293 cells: effect on intracellular adenosine levels, cell viability, and DNA methylation.

Hermes M, Osswald H, Riehle R, Piesch C, Kloor D.

Cell Physiol Biochem. 2008;22(1-4):223-36. doi: 10.1159/000149800. Epub 2008 Jul 25.

33.

Role of serum- and glucocorticoid-inducible kinase SGK1 in glucocorticoid regulation of renal electrolyte excretion and blood pressure.

Boini KM, Nammi S, Grahammer F, Osswald H, Kuhl D, Lang F.

Kidney Blood Press Res. 2008;31(4):280-9. doi: 10.1159/000151666. Epub 2008 Aug 28.

34.

The reno-vascular A2B adenosine receptor protects the kidney from ischemia.

Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Eltzschig HK.

PLoS Med. 2008 Jun 24;5(6):e137. doi: 10.1371/journal.pmed.0050137.

35.

Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation.

Hermes M, Geisler H, Osswald H, Riehle R, Kloor D.

Biochem Pharmacol. 2008 Jun 1;75(11):2100-11. doi: 10.1016/j.bcp.2008.02.031. Epub 2008 Mar 8.

PMID:
18395186
36.

Vasopressin regulation of inner medullary collecting ducts and compensatory changes in mice lacking adenosine A1 receptors.

Rieg T, Pothula K, Schroth J, Satriano J, Osswald H, Schnermann J, Insel PA, Bundey RA, Vallon V.

Am J Physiol Renal Physiol. 2008 Mar;294(3):F638-44. doi: 10.1152/ajprenal.00344.2007. Epub 2008 Jan 16.

37.

Lack of effect of extracellular adenosine generation and signaling on renal erythropoietin secretion during hypoxia.

Grenz A, Zhang H, Weingart J, von Wietersheim S, Eckle T, Schnermann J, Köhle C, Kloor D, Gleiter CH, Vallon V, Eltzschig HK, Osswald H.

Am J Physiol Renal Physiol. 2007 Nov;293(5):F1501-11. Epub 2007 Sep 12.

38.

Adenosine metabolism and its effect on methylation potential in cultured cells: methodological considerations.

Hermes M, Osswald H, Kloor D.

Cell Mol Biol (Noisy-le-grand). 2007 Jan 21;52 Suppl:OL874-81.

PMID:
17543225
39.

The role of the BK channel in potassium homeostasis and flow-induced renal potassium excretion.

Rieg T, Vallon V, Sausbier M, Sausbier U, Kaissling B, Ruth P, Osswald H.

Kidney Int. 2007 Sep;72(5):566-73. Epub 2007 Jun 20.

40.

Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury.

Grenz A, Zhang H, Hermes M, Eckle T, Klingel K, Huang DY, Müller CE, Robson SC, Osswald H, Eltzschig HK.

FASEB J. 2007 Sep;21(11):2863-73. Epub 2007 Apr 18.

PMID:
17442731
41.

Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors.

Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK.

Circulation. 2007 Mar 27;115(12):1581-90. Epub 2007 Mar 12.

PMID:
17353435
42.

Expression and localization of S-adenosylhomocysteine-hydrolase in the rat kidney following carbon monoxide induced hypoxia.

Kloor D, Hermes M, Fink K, Schmid H, Klingel K, Mack A, Grenz A, Osswald H.

Cell Physiol Biochem. 2007;19(1-4):57-66.

43.

Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia.

Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Köhle C, Kloor D, Thompson LF, Osswald H, Eltzschig HK.

J Am Soc Nephrol. 2007 Mar;18(3):833-45. Epub 2007 Jan 31.

44.

Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner.

Hambrock A, de Oliveira Franz CB, Hiller S, Grenz A, Ackermann S, Schulze DU, Drews G, Osswald H.

J Biol Chem. 2007 Feb 2;282(5):3347-56. Epub 2006 Nov 30.

45.

Role of S-adenosylhomocysteine hydrolase in adenosine-induced apoptosis in HepG2 cells.

Hermes M, Osswald H, Kloor D.

Exp Cell Res. 2007 Jan 15;313(2):264-83. Epub 2006 Oct 13.

PMID:
17097637
46.

Resistance of mice lacking the serum- and glucocorticoid-inducible kinase SGK1 against salt-sensitive hypertension induced by a high-fat diet.

Huang DY, Boini KM, Osswald H, Friedrich B, Artunc F, Ullrich S, Rajamanickam J, Palmada M, Wulff P, Kuhl D, Vallon V, Lang F.

Am J Physiol Renal Physiol. 2006 Dec;291(6):F1264-73. Epub 2006 Sep 26.

47.

Use of a hanging-weight system for isolated renal artery occlusion during ischemic preconditioning in mice.

Grenz A, Eckle T, Zhang H, Huang DY, Wehrmann M, Köhle C, Unertl K, Osswald H, Eltzschig HK.

Am J Physiol Renal Physiol. 2007 Jan;292(1):F475-85. Epub 2006 Aug 15.

48.

Effect of endothelin-1 on erythropoietin production in a rat model under normoxia and functional carbon monoxide-induced hypoxia.

Grenz A, Klein J, Köhle C, Freudenthaler S, Proksch B, Wu J, Wolf S, Osswald H, Gleiter CH.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Aug;373(5):342-8. Epub 2006 Jul 29.

PMID:
16896802
49.

[Economic aspects of treatment with diuretics].

Luippold G, Osswald H.

Pharm Unserer Zeit. 2006;35(4):346-52. Review. German. No abstract available.

PMID:
16886511
50.

Adenosine and kidney function.

Vallon V, Mühlbauer B, Osswald H.

Physiol Rev. 2006 Jul;86(3):901-40. Review.

Supplemental Content

Loading ...
Support Center